Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
Mao Ouyang(Central South University), Behnam Badie(City Of Hope National Medical Center), Jacob M. Berlin(City Of Hope National Medical Center), Ethan E. White(City Of Hope National Medical Center), Edwin R. Manuel(City Of Hope National Medical Center), Ian Zhang(Universidade Federal do Rio de Janeiro), Xuebo Chen(Jilin University), Yanyan Song(Second Affiliated Hospital of Jilin University), Qin Guo(Sun Yat-sen University), Leying Zhang(City Of Hope National Medical Center), Hui Ren(Second Affiliated Hospital of Jilin University), Hang Gao(Shanghai Public Security Bureau), Darya Alizadeh(CTI BioPharma (United Kingdom)), Yiming Weng(Wuhan University), Steven Vonderfecht(Amgen (United States)), Anna Da Fonseca(Universidade Federal do Rio de Janeiro), Sunny Shah(Gujarat Technological University)
Cited by 47
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
|Cancer Immunology Research|2019|437
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
|Frontiers in Immunology|2017|216